Group 1 - The core viewpoint of the news is the performance and holdings of the Huatai-PineBridge Medical Services Flexible Allocation Mixed A Fund, which has shown significant returns in recent months and has a strong portfolio in the healthcare sector [1][3]. - As of April 24, 2025, the fund's latest net value is 1.5450 yuan, reflecting a growth of 1.25% [1]. - The fund has achieved a return of 18.21% over the past month, ranking 2 out of 8 in its category, and a return of 30.60% over the past three months, ranking 1 out of 8 [1]. - Year-to-date, the fund has returned 28.32%, also ranking 1 out of 8 in its category [1]. Group 2 - The top ten stock holdings of the fund account for a total of 64.17%, with significant positions in companies such as Heng Rui Pharmaceutical (10.23%), Kelun Pharmaceutical (9.09%), and Bai Li Tianheng (8.94%) [1]. - The fund was established on June 18, 2015, and as of March 31, 2025, it has a total asset size of 4.408 billion yuan [1]. - The fund manager, Zhang Wei, has a strong background in biomedical studies and has held various positions in the pharmaceutical research field prior to managing this fund [2].

董事会 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 华英证券有限责任公司（下称"华英证券"）是深圳信立泰药业股份有限公 司（下称"公司"）2020 年度非公开发行股票的持续督导机构，其持续督导期已 于 2022 年 12 月 31 日届满。目前，华英证券正继续就公司未使用完毕的募集资 金相关情况履行持续督导责任。 近日，公司收到华英证券关于更名的通知，其名称"华英证券有限责任公司" 变更为"国联民生证券承销保荐有限公司"，并已完成工商变更登记，后续以新 公司名义开展业务与管理活动。 本次公司持续督导保荐机构名称变更不属于公司更换持续督导保荐机构事 项。公司与原"华英证券有限责任公司"签署的法律文件继续有效，由"国联民 生证券承销保荐有限公司"继续履行。 特此公告 深圳信立泰药业股份有限公司 证券代码：002294 证券简称：信立泰 编号：2025-027 深圳信立泰药业股份有限公司 关于持续督导机构更名的公告 二〇二五年四月二十三日 ...

医药板块持续走高 众生药业等多股涨停 智通财经4月22日电，午后医药板块持续走高，创新药方向继续领涨，众生药业、华森制药、富士莱涨 停，百利天恒、诺诚健华、新诺威、百济神州创历史新高，复旦张江、上海谊众、信立泰、热景生物等 涨幅靠前。消息面上，4月25日至4月30日，美国癌症研究协会（AACR）年会将在芝加哥召开。作为全 球规模最大的癌症研究会议之一，AACR年会一直是癌症领域最新研究成果的重要展示平台。 ...

证券代码：002294 证券简称：信立泰 编号：2025-025 深圳信立泰药业股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无增加、变更、否决提案的情况。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 3、本次股东大会以现场会议与网络投票相结合的方式召开。 4、本决议所称中小投资者是指单独或合计持有公司 5%以上股份的股东、公 司董事、监事、高级管理人员以外的其他股东。 一、会议召开情况 1、会议召集人：深圳信立泰药业股份有限公司第六届董事会 2、召开时间： 现场会议时间：2025 年 4 月 21 日下午 14:30 网络投票时间： 通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 4 月 21 日上 午 9:15 – 9:25，9:30 – 11:30，下午 13:00 – 15:00；通过深圳证券交易所互联网 投票系统投票时间为 2025 年 4 月 21 日上午 9:15 至下午 15:00。 3、会议召开地点：深圳市福田区福保街道福保社区红柳道 2 号 ...

北京市金杜（深圳）律师事务所 关于深圳信立泰药业股份有限公司 2024 年年度股东大会 的法律意见书 致：深圳信立泰药业股份有限公司 北京市金杜（深圳）律师事务所（以下简称本所）接受深圳信立泰药业股份有限 公司（以下简称公司）的委托，根据《中华人民共和国证券法》（以下简称《证券 法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券监督管理委 员会（以下简称中国证监会）《上市公司股东会规则（2025 年修订）》（以下简称 《股东会规则》）等中华人民共和国境内（以下简称中国境内，为本法律意见书之目 的，不包括中国香港特别行政区、中国澳门特别行政区和中国台湾地区）现行有效的 法律、行政法规、规章和规范性文件及现行有效的公司章程有关规定，指派律师出席 了公司于 2025 年 4 月 21 日召开的 2024 年年度股东大会（以下简称本次股东大会）， 并就本次股东大会相关事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限于： 1. 经公司 2023 年第一次临时股东大会审议通过的《深圳信立泰药业股份有限公 司章程》（以下简称《公司章程》）； 2. 公司于 2025 年 ...

Financial Data and Indicators - The basic earnings per share for Q1 2025 remained unchanged at 0.1800 CNY compared to Q1 2024, while it decreased from 0.1900 CNY in Q1 2023 [1] - The net asset per share increased by 8.4% to 8 CNY in Q1 2025 from 7.38 CNY in Q1 2024 [1] - The operating revenue for Q1 2025 was 10.62 billion CNY, a decrease of 2.66% from 10.91 billion CNY in Q1 2024, but an increase from 8.88 billion CNY in Q1 2023 [1] - The net profit for Q1 2025 was 2 billion CNY, unchanged from Q1 2024, but down from 2.11 billion CNY in Q1 2023 [1] - The return on equity (ROE) decreased by 8.1% to 2.27% in Q1 2025 from 2.47% in Q1 2024 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 76,343.2 million shares, accounting for 68.49% of the circulating shares, with a decrease of 456.69 million shares compared to the previous period [1] - The largest shareholder, Xinlitai Pharmaceutical Co., Ltd., holds 63,527.94 million shares, representing 57.00% of the total share capital, with no change [2] - The second largest shareholder, Shenzhen Xinlitai Pharmaceutical Co., Ltd. - Third Employee Stock Ownership Plan, holds 2,345.75 million shares, accounting for 2.10%, with no change [2] Dividend Distribution - The company has decided not to distribute dividends or transfer shares in this period [2]

Financial Performance - The company's revenue for Q1 2025 was ¥1,062,205,739.51, a decrease of 2.64% compared to ¥1,090,969,117.78 in the same period last year[4] - Net profit attributable to shareholders was ¥200,329,400.57, showing a slight increase of 0.03% from ¥200,265,316.30 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥192,122,030.16, down 4.64% from ¥201,466,979.90 in the previous year[4] - The net cash flow from operating activities decreased by 26.39% to ¥169,394,604.57 from ¥230,125,911.32 in the same period last year[4][9] - The company's net profit for the current period is 202,860,353.32, an increase from 198,111,870.96 in the previous period, representing a growth of approximately 3.9%[32] - The company reported a total comprehensive income of 201,407,824.70, slightly up from 198,712,294.65, marking an increase of about 0.35%[33] - The basic and diluted earnings per share remain stable at 0.18 for both periods[33] - The company recorded a decrease in total operating profit to 230,276,072.16 from 233,089,387.35, a decline of approximately 1.2%[32] - The income tax expense decreased to 25,100,922.40 from 32,622,692.31, reflecting a reduction of about 23.1%[32] Assets and Liabilities - Total assets at the end of the reporting period were ¥10,663,717,842.10, an increase of 1.89% from ¥10,465,603,624.18 at the end of the previous year[4] - Total liabilities decreased slightly to CNY 1,704,011,666.04 from CNY 1,713,287,268.66, a reduction of 0.5%[29] - Non-current assets decreased to CNY 5,968,857,412.75 from CNY 6,440,992,046.68, a decline of 7.3%[28] - The company's retained earnings increased to CNY 5,293,646,409.26 from CNY 5,093,317,008.69, reflecting a growth of 3.9%[29] Shareholder Information - The total number of common shareholders at the end of the reporting period is 27,261[14] - The largest shareholder, Xinlitai Pharmaceutical Co., Ltd., holds 56.99% of shares, totaling 635,279,380 shares, with 156,790,000 shares pledged[14] Investment and Fund Management - The company raised a total of RMB 195,187.12 million from issuing 68,800,535 shares at RMB 28.37 per share, with a net amount of RMB 193,206.57 million after deducting issuance costs[17] - As of March 31, 2025, the company has invested RMB 111,445.05 million of the raised funds, with RMB 1,506.13 million invested in the current year[17] - The balance of the raised funds account is RMB 94,135.59 million, with interest income of RMB 211.97 million during the reporting period[17] - The total amount of entrusted financial management is RMB 151,541.01 million, with no overdue amounts[22] - The expected annualized return rate for a non-principal guaranteed financial product is 3.65%, with an actual return of RMB 21.74 million[22] Cash Flow and Operating Activities - Cash and cash equivalents rose to CNY 1,419,473,525.84 from CNY 1,125,410,722.13, an increase of 26.2%[27] - The net cash flow generated from operating activities is 169,394,604.57, down from 230,125,911.32, indicating a decrease of approximately 26.4%[34] - Investment activities generated a net cash flow of 127,458,766.66, a significant improvement compared to a negative cash flow of -106,552,137.82 in the previous period[35] - The company received cash from investment recovery amounting to 835,000,000.00, a significant increase from 155,000,000.00 in the previous period[34] Research and Development - Research and development expenses increased slightly to CNY 108,135,215.18 from CNY 107,577,291.57, indicating a focus on innovation[31] - The company plans to continue promoting new products and increasing investment in innovative research and development despite the impact of generic drug policies[8][9] Financial Agreements and Returns - The company has a floating income agreement with a return of 3.50% for a total of 138.92 million yuan, maturing on May 22, 2024[23] - The company has a non-principal guaranteed agreement with a return of 2.90% for a total of 404.69 million yuan, maturing on August 28, 2024[23] - The company has a principal guaranteed fundraising agreement with a return of 3.70% for a total of 490.00 million yuan, maturing on November 5, 2024[23] - The company has a maximum term of 12 months for its agreements[23] - The company is actively managing idle fundraising resources in accordance with its cash management announcement[23]

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4] Core Viewpoints - The report emphasizes the upcoming launch of S086, a hypertension treatment, which is expected to have significant market potential. The company Sinopharm is highlighted as a key recommendation [3][8] - The report suggests that the pharmaceutical sector is poised for growth due to several factors, including innovation, international expansion, and an aging population. It also notes that the industry has completed a transition from old to new growth drivers [20][39] Summary by Sections 1. S086 - S086, developed by Sinopharm, is the second ARNI drug to enter clinical trials globally, with a significant market potential due to the high prevalence of hypertension in China [12][13] - The drug has shown superior efficacy in clinical trials, particularly in managing nighttime blood pressure and reducing uric acid levels, which positions it favorably against competitors like Novartis' Entresto [12][13] 2. Industry Perspective - The pharmaceutical index has shown a decline of 0.36% from April 14 to April 18, with a year-to-date decline of 1.45%. The report notes that the sector is experiencing a mixed performance with both rising and falling stocks [20][25] - The report identifies key investment themes: innovation, international expansion, and the impact of an aging population on healthcare demand [20][39] 3. Investment Recommendations - The report recommends focusing on innovative pharmaceutical companies and medical devices, particularly those with strong international growth potential and those benefiting from domestic policy support [39][41] - Specific companies highlighted for investment include Sinopharm, Hengrui Medicine, and Kelun Pharmaceutical, among others [39][42]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company is experiencing sustained high growth in its Aliskiren ester product line, and an innovative pipeline is about to form [5] - The company reported a revenue of 4.012 billion yuan for 2024, representing a year-on-year growth of 19.22%, and a net profit attributable to shareholders of 602 million yuan, up 3.71% year-on-year [6] - The company is increasing its R&D investment, which accounted for 25.35% of revenue in 2024, amounting to 1.017 billion yuan [6] Financial Summary - Revenue projections for the company are as follows: 3.365 billion yuan in 2023, 4.012 billion yuan in 2024, 4.505 billion yuan in 2025E, 5.436 billion yuan in 2026E, and 6.278 billion yuan in 2027E [5][7] - The projected net profit for 2025 is 661 million yuan, with a year-on-year growth rate of 9.88% [5] - The company’s earnings per share (EPS) are expected to be 0.59 yuan in 2025, with a projected price-to-earnings (P/E) ratio of 60.80 [5][7] - The company’s total assets are projected to reach 10.998 billion yuan in 2025, with total liabilities of 1.980 billion yuan [7]

证券代码：002294 证券简称：信立泰 深圳信立泰药业股份有限公司投资者关系活动记录表 编号：20250418 | | □特定对象调研 □分析师会议 | | --- | --- | | 投 资 者 关 | □媒体采访 √业绩说明会 | | 系 活 动 类 | □新闻发布会 □路演活动 | | 别 | □现场参观 □电话会议 | | | □其他（请文字说明其他活动内容） | | 活 动 参 与 | 全体投资者 | | 人员 | | | 时间 | 2025 年 4 月 18 日 15:00-17:00 | | | 深圳证券交易所"互动易平台"http://irm.cninfo.com.cn"云访谈" | | 地点 | 栏目 | | 形式 | 网络远程方式 | | 上 市 公 司 | | | 接 待 人 员 | 董事、董事会秘书：杨健锋；财务负责人：孔芸 | | 姓名 | | | | 首先，杨健锋先生对公司情况进行了介绍；然后公司参会领 | | | 导对投资者关注的问题进行了回复。 | | 投 资 者 关 | | | | 1.尊敬杨总：信立坦 2024 年销售额 15 亿元（占营收 37.4%）， | | 系 活 ...